







	Containment phase		Mitigatio	on phase	
					$ \rightarrow $
	Patients with specific epidemiological links	Some community transmission, but frequently with epidemiological links	Wider community transmission, rarely with epidemiological links	Clustered community transmission with ongoing local outbreaks	SARS-CoV-2 circulation established in the community
	***********	************	************	*****	*************
	******	***********	************	*****	*************
	*****	***********	***********	************	********
	*********	***********	**********	*********	*************
	************	***********	************	************	*********
Likely strategy for PPE use	HCWs working directly with COVID-19 patients or with patients fulfiling case definition (clinical plus epidemiological)	HCWs working directly with COVID-19 patients or with patients fulfilling case definition (clinical criteria only)	HCWs working on units also managing COVID-19 patients or possible cases for all patient contacts	All HCWs who with patients	o have contact 5
					All hospital staff (including administrative and support services)
Most likely source of HCW infection at work	Exposure to patients not fulfilling case definition (no epidemiological criteria, mild or no symptoms, atypical presentations)	Exposure to patients with mild or n presentations	to symptoms or those with atypical	Exposure to patients when there ar	e breaches in optimal PPE use
	Exposure to small number of infect acquired infection from patients a	ted colleagues who themselves s above	Exposure to infected colleagues with from patient care (meetings, break t	various pathways of SARS-CoV-2 actimes)	quisition at the bedside and away
Most promising approach towards identifying SARS-CoV-2	Standard contact tracing approaches	Encourage self-monitoring or supp direct patient contact with rapid te	ort active monitoring of HCWs with sting of HCWs	Encourage self-monitoring and prostaff	ovide rapid testing to all hospital





	Types a	of Rev	<i>iews</i>	
ELEVIER DETERMENT OF THE THE STATE OF THE ST	British Education Berlew Finder Constraints A marative review A mar	Ren C C A M M M M M M M M M M M M M M M M M M	International Annual of Stark Strategy and Stark Strategy and Strategy	Discontract of the contract of the conteont of the contract of the contract of the contract of the contra
	Zahayi Mumi Q, Muh B J, Peter, Chely Sterr, Galahi Tudinana, Alexa Muketar ar <b>Data Mumi</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Sector</b> <b>Se</b>	d Edoardo Aromataes currently there exists Effe weeker approach when in indications behave investigate fund is not investigate research investigate research in bystemätic verview i currently approaches, merkers atti mequire rigoroux currently atti mequire rigoroux curre	To do scoping review is to identify knowled a body of literature, a or to investigate resu As precursors to syste	if the purpose lge gaps, scope clarify concepts earch conduct. ematic reviews.







			1		
Category of study designs	Methodological quality criteria	Yes	No	Responses Can't tell	Comments
Screening questions	S1 Are there clear research questions?				
(for all types)	S2. Do the collected data allow to address the research questions?				
( ··· ·/F - ·/	Further appraisal may not be feasible or appropriate when the answer is 'No' or 'Can't tell' to one or both screening	avestio	ns		
1 Qualitative	1.1. Is the multitative approach appropriate to answer the research question?	questio			
r. Quantauve	1.1. Is the qualitative approach appropriate to answer the research question?				
	1.2. Are the findings adaptately derived from the data?				
	1.5. Are the interpretation of results sufficiently substantiated by data?				
	1.5. Is the interpretation of results sufficiently substantiated by data:				
2 Ouentitation	2.1. Is and emiration encounterly exchanged?				
2. Quantitative	2.1. Is failed mization appropriately performed?				
trials	2.2. Are there complete outcome date?				
	2.4. Are outcome assessors blinded to the intervention provided?				
	2.5 Did the participants adhere to the assigned intervention?				
2. Outration and	2.1 As the anticipants conceptation of the transformation?		_		
5. Quantitative non-	3.1. Are the participants representative of the target population?		-		
	3.2. Are there complete outcome data?				
	3.4. Are the confounders accounted for in the design and analysis?				
	3.5 During the study period, is the intervention administered (or exposure occurred) as intended?				
4 Quantitative	4.1 Is the sampling strategy relevant to address the research question?				
descriptive	4.2. Is the sample conceptative of the target nonulation?	-			
uescriptive	4.3 Are the measurements approximate?	-			
	4.4. Is the risk of nonresponse bias low?	-			
	4.5. Is the statistical analysis appropriate to answer the research question?				
5 Mixed methods	5.1 Is there an adequate rationale for using a mixed methods design to address the research question?	-			
5. Milaco metilous	5.2. Are the different components of the study effectively integrated to answer the research question?				
	5.3 Are the outputs of the integration of qualitative and quantitative components adequately interpreted?				
	5.4. Are divergences and inconsistencies between quantitative and qualitative results adequately addressed?				
	5.5 De de different en contra da de de de de de de de different en contra de la contra de la contra de	-			











#	Study charac	retristics	Outcome characteristics				Findings				QS
	Study [ref] Country	Population/ sample size	Type of mental health	Measurements tool (range of score)	Definition of outcome	Measure	Total	By severity of outcome	By sex	By population	(0-1
ī	Lai et al. [4] China	Medical staff T: 1257 P: 493 (92296) N: 764 (60,77%)	Depression Anxiety Insomn is Distress	PHQ-9 (0-27) GAD-7 (0-21) IST-7 (0-28) IE-22 (0-88)	PHQ-9, normal (0–4), mild (5–9), mod (10–14), secure (15–21) GAD-7, normal (0–4), mild (5–9), mod (10–14), sets format(0–7), arb (8–14), normal (0–8),mild (9–25), mod (26–43), severe (44–485)	Prevalence (%)	Depression 50.4% Anxiety 44.6% Insomnia 34.0% Distress 71.5%	Depression Mid: 35.6% Mod: 8.6% Severe: 6.2% Antiety Mid: 32.3% Mod: 7.0% Severe: 5.3% Insonnia Subhueshold: 26.2% Mod: 6.8% Severe: 10.5%	Depression M: 41.7% F: 53.2% Anxiety M: 35.5% F: 47.4% Insomnia M: 29.1% F: 35.5% Distress M: 58.4% F: 75.6%	Depression N: 53.5% P: 45.6% Anxiety N: 47.1% P: 40.6% Imoon dia N: 38.2% P: 27.4% Distress N: 74.5% P: 66.9%	13
2	Kang et al. [14] China	Medical staff T: 994 P: 183 N: 811	Mental health disturbances	PHQ-9 (0-27) GAD-7 (0-21) ISI-7 (0-28) IE-22 (0-88)	According to these four questionnaires by Ward method and using cluster analysis	Prevalence (%)	63%	Mild 34,4% Mod 22,4% Severe 6,2%	M: 56.9% F: 64.1%	N: 64.11% P: 58.46%	п
3	Luetal [18] China	Medical staff P + N: 2042 Administrative staff: 257	Fear Anxiety Depression	NRS (0-10) HAMA (0-70) HAMD (0-85)	Fear scale, 0-3 (no/mid) 4-6 (modente) 7-10 (severekteme) HAMA, 0-6 (no) 0-6 (no) 2-14 (severekteme) HAMD, 0-6 (no) 7-23 (mildimodente) ≥24 (severe/extreme)	Prevalence (%)	Fear 70.6% Anxiety 25.5% Depression 12.1%	Fear notmik: 29,4% Mod: 43,9% severe/extreme: 26,7% Anxlety mildtmod: 22,6% severe/extreme: 2,9% Depression no: 87,9% mildtmodente: 11,8% severe/extreme: 0,3%	NR	Fear Medical staff: 70.6% Administra the staff: 58.4% Anxiety Medical staff: 25.5% Administra the staff: 20% Depression Medical staff: 12.1% Administra the staff: 8.2%	12
4		Medical staff		SDS SAS	NA		SDS	NR	NR	SDS	11

#	Study charac	teristics	Outcome characteristics				Findings				QS
	Study [ref] Country	Population/ sample size	Type of mental health	Measurements tool (range of score)	Definition of outcome	Measure	Total	By severity of outcome	By sex	By population	(0-14)
	Ling et al. [23] China	T: 59 COVID-19 department's staff: 38 Other department's staff: 21	Anxiety Depression			Mean score ± SD	30.23 ±7.98 SAS 28.54 ±5.16			COVID-19 department's staff: 29.61 ± 8.02 Other department's staff: 31.36 ± 7.92 SAS COVID-19 department's staff: 27.88 ± 5.32 Other department's staff: 29.04 ± 5.22	
5	Xiao et al. [6] China	Medical staff T: 180	Anxiety Self-efficacy Stress Sleep quality Social support	SSRS (7-56) SAS (0-80) GSES (10-40) SASR (0-150) PSQI (0-21)	NA	Mean score ± SD	SSRS 34.172±10.263 GSES 2.267±0.767 SAS 55.256±14.183 SASR 77.589±29.525 PSQI 8.583±4.567	NR	NR	NR	12
6	Li et al. [12] China	Medical staff T: 740 GP: 214 FLN: 234nFLN: 292	Vicarious trauma	38-190	NA	Median (25th-75th)		NR	NR	GP 75.5 (62-88.3) FLNs 64 (52-75) nFLNs 75.5 (63-92)	10
7	Mo et al. [19] China	Nurse N: 180	Anxiety Stress	SOS (22-110) SAS (20-80)	NA	Mean score ± SD	SOS 39.91±12.92 SAS 32.19±7.56	NR	NR	NR	13
8	Dai et al. [20] China	Medical staff T: 4357 N: 2343 (53.77%) P: 1419 (32.56%) Technician: 437 (10%)	Psychological distress	GHQ-12 (0-12)	GHQ≥3	Prevalence (%)	39.1%	NR	M: 32.2% F: 41.2%	P: 39% N: 41.3% Technician: 30.7% Support staff: 30.4%	12





21







WV	ww.webbertraining.com/schedulep1.php
January 27, 2022	CLINICAL SYNDROMES AND CONDITIONS WARRANTING EMPIRIC TRANSMISSION BASED PRECAUTIONS Speaker: Dr. Jennifer Cole, Avanti Hospitals, California
February 3, 2022	VACCINE HESITANCY WHAT'S HAPPENING? Speaker: Prof. Rodney Rohde, Texas State University
February 8, 2022	(FREE European Teleclass) THREE EARLY PIONEERS – WHO CAN STILL TEACH US A THING OR TWO Speaker: Dr. Evonne Curran, Glasgow Caledonian University, Scotland
February 10, 2022	RETHINKING SOLUTIONS FOR PUBLIC HEALTH PROBLEMS: A HOLISTIC ONE HEALTH SOCIAL SCIENCE (OHSS) SYSTEMS APPROACH Speaker: Dr. Laura C. Streichert, One Health Commission
February 17, 2022	ASSESSING THE CLINICAL ACCURACY OF A HAND HYGIENE SYSTEM Speaker: Dr. Marco Bo Hansen, Copenhagen University Hospital, Denmark
February 24, 2022	HEALTHCARE INFORMATICS LESSONS FROM THE PANDEMIC Speaker: Prof. Keith Woeltje, Medical College of Wisconsin
March 3, 2022	(FREE Teleclass Denver Russell Memorial Teleclass Lecture) BENEFITS AND POTENTIAL UNINTENDED CONSEQUENCES OF ROUTINE CHLORHEXIDINE BATHING IN HEALTHCARE FACILITIES Speaker: Prof. Mary Hayden, Rush University Medical Center, Chicago

